Human/Mouse alpha-Fetoprotein/AFP Antibody

Detection of alpha ‑Fetoprotein/AFP by Western Blot. Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line. PVDF membrane was probed with 0.5 µg/mL of Mouse Anti-Human/Mouse a-Fetoprotein/AFP Monoclonal Antibody (Catalog # MAB1368) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for a-Fetoprotein/AFP at approximately 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

alpha ‑Fetoprotein/AFP in HepG2 Human Cell Line. a-Fetoprotein/AFP was detected in immersion fixed HepG2 human hepatocellular carcinoma cell line using Mouse Anti-Human/Mouse a-Fetoprotein/AFP Monoclonal Antibody (Catalog # MAB1368) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Detection of alpha ‑Fetoprotein/AFP in HepG2 Human Cell Line by Flow Cytometry. HepG2 human hepatocellular carcinoma cell line was stained with Mouse Anti-Human/Mouse a-Fetoprotein/AFP Monoclonal Antibody (Catalog # MAB1368, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.

Detection of Human alpha ‑Fetoprotein/AFP by Simple Western^TM. Simple Western lane view shows lysates of HepG2 human hepatocellular carcinoma cell line, loaded at 0.2 mg/mL. A specific band was detected for alpha ‑Fetoprotein/AFP at approximately 70 kDa (as indicated) using 5 µg/mL of Mouse Anti-Human/Mouse alpha ‑Fetoprotein/AFP Monoclonal Antibody (Catalog # MAB1368). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Western Blot Shows Human alpha -Fetoprotein/AFP Specificity by Using Knockout Cell Line. Western blot shows lysates of HepG2 human hepatocellular carcinoma parental cell line and a-Fetoprotein/AFP knockout HepG2 cell line (KO). PVDF membrane was probed with 0.1 µg/mL of Mouse Anti-Human/Mouse a-Fetoprotein/AFP Monoclonal Antibody (Catalog # MAB1368) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for a-Fetoprotein/AFP at approximately 70 kDa (as indicated) in the parental HeLa cell line, but is not detectable in knockout HeLa cell line. GAPDH (Catalog # AF5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

alpha -Fetoprotein/AFP Specificity is Shown by Flow Cytometry in Knockout Cell Line. a-Fetoprotein/AFP knockout HepG2 hepatocellular carcinoma cell line was stained with Mouse Anti-Human a-Fetoprotein/AFP Monoclonal Antibody (Catalog # MAB1368, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) followed by PE-conjugated Goat anti-Mouse IgG Secondary Antibody (Catalog # F0102B). No staining in the a-Fetoprotein/AFP knockout HepG2 cell line was observed. View our protocol for Staining Membrane-associated Proteins.

Detection of Human alpha-Fetoprotein/AFP by Immunocytochemistry/Immunofluorescence Functional glycosylation of alpha ‐dystroglycan and characterization of dystroglycanopathy patient‐specific iPSCsCurrent model of the core M3 functional glycan structure on alpha ‐dystroglycan and enzymes involved in its synthesis. ECM ligands, such as laminins, bind to the Xyl‐GlucA disaccharide repeats (IIH6 epitope). Man, mannose; GlcNAc, N‐acetylglucosamine; GalNAc, N‐acetylgalactosamine; Rbo5P, ribitol‐5‐phosphate; Xyl, xylose; GlcA, glucuronic acid.Representative images of immunostaining demonstrate that FKRP‐iPSCs express specific pluripotency‐associated markers, including NANOG, OCT4, Tra‐1‐60, and SSEA4.FKRP‐iPSCs have a normal karyotype.In vitro differentiation of FKRP‐iPSCs to cells representing ectoderm ( beta ‐III Tubulin, Tuj1), mesoderm (SMA, smooth muscle actin), and endoderm (AFP, alpha ‐fetoprotein).Data information: Scale bars, 50 μm. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31566294), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human alpha-Fetoprotein/AFP by Immunocytochemistry/Immunofluorescence Verification of the pluripotency of the iPSC lines with the TDP-43 A90V mutation.(A) Fluorescence microscopy images of the expression of the pluripotency markers NANOG, OCT4, SSEA4, TRA-1-60, and TRA-1-81 in control (37L25) and patient (36L10) iPSC lines. Scale bar: 20 µm. (B) All iPSC lines differentiated into cells of the three germ layers, as shown by expression of desmin (mesoderm), TUJ1 (ectoderm), and alpha-fetoprotein (AFP, endoderm). These analyses indicate iPSC lines generated here are indeed pluripotent. Scale bar: 20 µm. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0076055), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse alpha-Fetoprotein/AFP by Immunohistochemistry Unchanged tumor marker levels in liver, lung, brain, and skin of plasma-treated mice. Representative images of immunohistochemistry of different tumor markers (TM): AFP (I) in liver, beta 2M in brain (II), CEA in lung (III), as well as NSE staining in skin tissue (IV) after one year in positive control (+ve ctrl, left) and plasma-treated (right) animals (A). Scale bar 50 µm (right columns) or 100 µm (left columns). Using ELISA, we analyzed AFP (I), and calcitonin (CT) (II), a TM of medullary thyroid carcinoma, in blood serum (B; * p < 0.05; (n > 9). The mRNA expression levels of five TM and beta -actin in liver, brain, lung, and ear skin tissues from plasma- and untreated (ctrl) mice were compared with organs from a HCC-bearing mouse (+ve ctrl). At least three independent experiments were performed and summarized in the indicated experimental groups (m, male; f, female). AFP, alpha -fetoprotein; NOPE, neighbor of Punc 11; beta 2M, beta 2-microglobulin; NSE, neuron specific enolase; CEA, carcinoembryonic antigen (C). Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/1422-0067/18/4/868), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human alpha-Fetoprotein/AFP by Immunocytochemistry/Immunofluorescence Pertussis toxin does not affect the maintenance of pluripotency pluripotent stem cell colonies or the ability to form all three embryonic germ layers.(A) Pertussis toxin does not affect the maintenance of pluripotency of hES or hiPS cells as assessed by the expression of the pluripotency markers Nanog, Oct4, Sox2, TDGF1, and ZFP42 by quantitative real-time PCR. (B) Immunocytochemistry of TRA-1-81 (green) and Oct-3/4 (red) also did not reveal differences between hES or hiPS cells treated with pertussis toxin and control treatments in pluripotent stem cell colonies. Nuclei were stained with Hoechst (blue). Scale bar, 200 µm. (C) hES or iPS cells treated with pertussis toxin formed embryoid bodies and differentiated into cell types of the all three embryonic germ layers as assessed by immunocytochemistry for alpha -fetoprotein (a marker of endoderm), alpha -smooth muscle actin (mesoderm) and beta III-tubulin (ectoderm). Scale bar, 100 µm. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/19936228), licensed under a CC-BY license. Not internally tested by R&D Systems.